{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:57:13Z","timestamp":1793383033700,"version":"4.5.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of the Study:<\/jats:title>\n            <jats:p>The purpose of the study was to evaluate the intraocular pressure (IOP)-lowering effect and tolerability of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>This prospective, noncomparative, interventional case series study included 35 patients with primary open angle glaucoma, in whom the glaucoma was poorly controlled with maximum medical therapy before starting the treatment with ripasudil. Ripasudil was instilled twice a day as adjunctive therapy to the ongoing glaucoma treatment. The primary end point was the degree of IOP reduction after 3 months of treatment, whereas the secondary end points were the percentage of patients reaching the predefined target IOP and the incidence of adverse events.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We examined 35 eyes of 35 patients with primary open angle glaucoma. The IOP reduction (relative percentage IOP reduction) from baseline was \u22122.8 mm Hg (\u221215.5%; 95% confidence interval, \u22121.6 to \u22123.9 mm Hg; <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001) after 3 months of treatment. The predefined target IOP was achieved in 48.5% (17\/35) of the patients. The adverse events were conjunctival hyperemia (all patients), allergic conjunctivitis (2 patients), and ophthalmalgia (1 patient).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The addition of ripasudil was effective in lowering the IOP in patients with glaucoma poorly controlled with maximal medical therapy; moreover, the drug was well tolerated. In 48.5% of the patients in whom the predefined target IOP was achieved, this adjunctive therapy helped avoid glaucoma surgery at least in the short term.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ijg.0000000000000552","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T17:42:44Z","timestamp":1474479764000},"page":"96-100","source":"Crossref","is-referenced-by-count":27,"title":["Efficacy of the Additional Use of Ripasudil, a Rho-Kinase Inhibitor, in Patients With Glaucoma Inadequately Controlled Under Maximum Medical Therapy"],"prefix":"10.1097","volume":"26","author":[{"given":"Hiroshi","family":"Inazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayoshi","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Kadonosono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0002-9394(00)00538-9","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration","volume":"130","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ophtha.2008.08.051","article-title":"Visual field progression in the Collaborative Initial Glaucoma Treatment Study: the impact of treatment and other baseline factors","volume":"116","author":"Musch","year":"2009","journal-title":"Ophthalmology"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/02713683.2013.874444","article-title":"Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits","volume":"39","author":"Isobe","year":"2014","journal-title":"Curr Eye Res"},{"key":"R5-20230912","first-page":"137","article-title":"Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility","volume":"42","author":"Honjo","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1167\/iovs.11-8018","article-title":"The effect of rho-associated protein kinase inhibitor on monkey Schlemm\u2019s canal endothelial cells","volume":"53","author":"Kameda","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archopht.116.5.633","article-title":"H-7 disrupts the actin cytoskeleton and increases outflow facility","volume":"116","author":"Tian","year":"1998","journal-title":"Arch Ophthalmol"},{"key":"R8-20230912","first-page":"1029","article-title":"Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632","volume":"42","author":"Rao","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.exer.2004.08.029","article-title":"Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humor outflow facility","volume":"80","author":"Rao","year":"2005","journal-title":"Exp Eye Res"},{"key":"R10-20230912","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jamaophthalmol.2013.323","article-title":"Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115","volume":"131","author":"Tanihara","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ajo.2013.05.016","article-title":"Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-angle glaucoma and ocular hypertension","volume":"156","author":"Tanihara","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","article-title":"One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension","volume":"94","author":"Tanihara","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/S0161-6420(99)90461-X","article-title":"Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy","volume":"106","author":"thoe Schwartzenberg","year":"1999","journal-title":"Ophthalmology"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/archophthalmol.2010.131","article-title":"Meta-analysis of the efficacy and safety of \u03b12-adrenergic agonists, \u03b2-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs","volume":"128","author":"Tanna","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"19640","DOI":"10.1038\/srep19640","article-title":"Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm\u2019s canal endothelial cells","volume":"6","author":"Kaneko","year":"2016","journal-title":"Sci Rep"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajpath.2014.10.023","article-title":"RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork","volume":"185","author":"Pattabiraman","year":"2015","journal-title":"Am J Pathol"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/40187","article-title":"Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension","volume":"389","author":"Uehata","year":"1997","journal-title":"Nature"}],"container-title":["Journal of Glaucoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00061198-201702000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T21:36:05Z","timestamp":1694554565000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00061198-201702000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/ijg.0000000000000552","relation":{},"ISSN":["1057-0829"],"issn-type":[{"value":"1057-0829","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}